Trial
NCT03135028
Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Gilead Sciences
Collaborators
—
Condition
Hematologic Malignancy
Intervention
Entospletinib
Why stopped
No signal of efficacy with Entospletinib
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-06